Safety and Efficacy of AKCEA-APO(a)-1 to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose -Ranging Trial

Authors
Publication date
1 January 2018
Publisher
'Ovid Technologies (Wolters Kluwer Health)'

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Kölner UniversitätsPublikationsServer

    redirect
    oaioai:USBKOELN.ub.uni-koeln.de:1...
    Last time updated on 22/10/2020